Products / Services

At present, the company has established extensive, in-depth and long-term cooperative relationships with many hospitals, and researches on multiple cancers such as lung cancer, colorectal cancer and gynecological tumors. The research direction covers the screening of early tumor markers and the prognosis. evaluation, tumor heterogeneity molecular classification and other fields, and

achieved fruitful results.

Genecast Hereditary (FAM)

Genecast Hereditary (FAM) is our NGS-based early screening test for multi-gene identification of over 50 types of hereditary cancer syndromes in 25 solid tumors. 

High-risk populations, who are at risk for hereditary cancer, may benefit from undergoing Genecast Hereditary (FAM) testing to provide cancer risk assessment. 

Genecast Hereditary (FAM) sequences exons and detects SNVs and Indels in 87 genes in ctDNA extracted from blood cell samples and oral swab samples. 

It combines genetic screening by sequencing the ctDNA of blood cell samples and oral swab samples with analysis against international authoritative databases, including ClinVar and dbSNP, and our proprietary algorithm, to provide risk assessment of over 50 types of hereditary cancer syndromes in 25 solid tumors based on ACMG and NCCN guidelines.

The sensitivity, specificity, and positive predictive value (“PPV”) for all exons and splicing regions screened by Genecast Hereditary (FAM) are greater than 99%, and the consistency of SNVs and Indels in the repeatability verification is greater than 96%.